Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)

NCT ID: NCT00744900

Last Updated: 2009-07-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-30

Brief Summary

NSCLC patients often have cerebral metastasis : 10% at diagnosis and 40% during disease management. Neurosurgery is not indicated in the majority of cases because of presence of several lesions in the brain, failure of primary tumor control or presence of extra-cerebral metastasis. Cerebral metastasis lead to death in 30 to 50% of these cases. Management of these patients in this situation is based on supportive care and whole-brain radiotherapy. The place of chemotherapy for patients with good performance status was discussed for a long time and it is now admitted. However, the place of new drugs such as pemetrexed, which is currently used as a second line treatment for NSCLC, needs to be further studied. It is known that pemetrexed when added to cisplatin for treatment of NSCLC provides a similar effectiveness when compared to other drugs associations commonly used in this indication. In addition, Cisplatin with Pemetrexed probably present a better safety profile.

The present study is based upon the hypothesis stipulating that the association cisplatin-pemetrexed will be at least as efficient as the others association currently used for treatment of NSCLC and will present a better safety profile. The primary objective of this study is overall response rate on brain metastasis according to RECIST criteria. Secondary judgment criterias are : Overall response rate, PFS after first-line CDDP plus pemetrexed, safety profile, quality of life, neurological symptoms, overall survival.

The trial will enroll up to 45 patients in this single-arm two-stage sequential phase II study with the possibility of stopping the study early because of lack of efficacy.

Conditions

Lung Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Group Type: EXPERIMENTAL

Pemetrexed, cisplatin

Intervention Type: DRUG

Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.

Interventions

Pemetrexed, cisplatin

Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with cytologically or histologically confirmed NSCLC.
• Patient with brain metastasis not amenable to surgery or radiosurgery with curative intent
• At least one brain measurable lesion using RECIST criteria
• ECOG Performance Status ≤2
• No prior chemotherapy for this cancer
• Prior surgery is allowed provided there is a relapse or progression after the procedure.
• Adequate organ function including the following: Adequate bone marrow reserve: absolute neutrophil count (ANC) superior or equal to 1.5 X109/L, platelets superior or equal to 100 X 109/L, and hemoglobin superior or equal to 9 g/dL; Hepatic: bilirubin <1.5 times the upper limit of normal (ULN), alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) <3xULN (or <5xULN with liver metastases); Renal: Calculated creatinine clearance (CrCl) superior or equal to 45mL/min based on the standard Cockroft and Gault formula
• Signed informed consent document from the patient
• Patient must be at least 18 years of age.
• Estimated life expectancy of at least 12 weeks.
• Effective contraception (men and women) for and during the 6 months following the end of treatment

Exclusion Criteria

• Symptomatic brain metastasis
• Have received prior radiotherapy for brain metastasis
• Unable or unwilling to take folic acid, vitamin B12 supplementation or dexamethasone (or equivalent corticosteroid); or any other inability to comply with protocol or study related procedures.
• A prior malignancy other than NSCLC, except carcinoma in situ of the cervix or non-melanoma skin cancer, adequately treated low grade [Gleason score <6] localized prostate cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence
• Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete study.
• Inability to discontinue administration of aspirin at a dose >1.3g/day or other non-steroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days prior for long-acting agents such as piroxicam).
• Presence of fluid accumulations in third spaces, e.g., ascite or pleural effusion, which can be detected clinically (during physical examination), and which cannot be adequately controlled by drainage or other procedures prior to inclusion in the study.
• Peripheral neuropathy > CTC Grade 2
• Patient compliance or geographic distance precluding adequate follow up.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Brest

OTHER

Sponsor Role: lead

Responsible Party

CHU BREST, Institut de Cancerologie et d'Hématologie

Principal Investigators

Gilles Robinet, MD

Role: PRINCIPAL_INVESTIGATOR

CHU Brest

Barlesi Barlesi, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique Hôpitaux de Marseille

Isabelle Monet, MD

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier, Créteil

Locations

Centre Hôspitalier du Pays d'Aix, Service des Maladies Respiratoires

Aix-en-Provence, , France

CHU d'Angers, Service de Pneumologie

Angers, , France

Médecine 4, C.H.G. de la Fontonne Antibes

Antibes, , France

CHU brest, institut de cancérologie et d'hématologie

Brest, , France

Centre François Baclesse

Caen, , France

Centre Hospitalier René Dubos - Pontoise, Service d'Oncologie - Hématologie Clinique

Cergy-Pontoise, , France

Centre Hospitalier, Service de Pneumologie

Charleville, , France

CHI, Service de Pneumologie

Créteil, , France

Pneumologie, Centre hôspitalier, DRAGUIGNAN

Draguignan, , France

CH GAP

Gap, , France

Centre Hospitalier Départemental, Service de Pneumologie,

La Roche-sur-Yon, , France

Hôpital A. Mignot, Service de Pneumologie

Le Chesnay, , France

Hopital de la Croix Rousse

Lyon, , France

Centre Hôspitalier, Service de Pneumo-Neuro

Mantes-la-Jolie, , France

Hôpital Sainte Margueritte

Marseille, , France

Serv. de Pneumo-Allergo, CH de Martigues

Martigues, , France

Serv. de Pneumo - Hôpital St Antoine

Paris, , France

Service Pneumologie, Pavillon 1A, CH de Lyon-Sud

Pierre-Bénite, , France

Hôpital Pontchailloux, Service de Pneumologie.

Rennes, , France

CHG, Service de Pneumologie

Roanne, , France

Luc THIBERVILLE

Rouen, , France

CHU de ROUEN, Hôpital Bois Guillaume, Serv. de Pneumo.

Rouen, , France

Institut de Cancérologie de la Loire

Saint-Priest-en-Jarez, , France

CHU, Service du Pr. Carles

Toulouse, , France

Pneumologie, Centre Hospitalier

Villefranche-sur-Saône, , France

Countries

France

Other Identifiers

RB 07.103

Identifier Type: -

Identifier Source: secondary_id

GFPC 07-01

Identifier Type: -

Identifier Source: org_study_id